About A public-private partnership that supports the discovery of new medicines through open access research. About SGC Partners Research Laboratories SGC-Toronto SGC-UNC SGC-Frankfurt SGC-Karolinska SGC-Neuro Governance Collaborators Open Science Equity, Diversity and Inclusion Impact Science and Resources Proteins Structure Gallery Expression Vectors Plasmids Constructs Production Protocols ChromoHub Phylogenetic Trees UbiHub Phylogenetic Trees ChemBioPort Chemical Probes Program CHEMICAL PROBES Donated chemical probes Chemical Handles Human Kinase Chemical Probe Program ANTIBODIES TARGET ENABLING PACKAGES (TEPs) TISSUE PLATFORM Open Lab Notebooks Open Chemistry Network PUBLICATIONS People Global Aled Edwards, CEO Susan McCormick, CFO Max Morgan, General Counsel and Public Policy Director SGC Toronto Cheryl Arrowsmith Dalia Barsyte-Lovejoy Takis Prinos Matthieu Schapira Levon Halabelian Rachel Harding SGC UNC Tim Willson Alison Axtman David Drewry Peter J. Brown Rafael M. Couñago SGC UCL Mat Todd SGC Karolinska Michael Sundström Opher Gileadi SGC Frankfurt Stefan Knapp Susanne Müller-Knapp Thomas Hanke Vladimir Rogov Krishnal Saxena Andreas Joerger Václav Němec Andreas Krämer Sandra Röhm SGC Neuro Edward Fon Thomas Durcan Jean-François Trempe Ziv Gan-Or Peter McPherson Carl Laflamme Roxanne Lariviere News & Outreach News & Events News from SGC Press Releases Events Blog Tweets by thesgconline Careers
A public-private partnership that supports the discovery of new medicines through open access research.
A-196 A selective chemical probe for SUV420H1/H2This probe is available from Sigma, Cayman Chemical and Tocris. The control may be requested by clicking here. For any inquiries please contact proberequests@thesgc.org.group newOverview Histone H4 lysine 20 methylation is emerging as a crucial modification to ensure genomic integrity both in the absence and presence of genotoxic stress [1]. The majority of histone H4 methylation is detected in the lysine 20 (H4K20) and is evolutionarily conserved from yeast to human [2,3]. Each methylation state results in distinct biology: dimethylated H4K20 (H4K20me2) is involved in DNA replication and DNA damage repair, and trimethylated H4K20 (H4K20me3) results in silenced heterochromatic regions [1]. Loss of histone H4 lysine 20 trimethylation (H4K20me3) is characteristic of human cancer and a potential prognostic marker in many types of cancers [4]. SUV420H1 and SUV420H2 are two highly homologous methyltransferases that di- and tri-methylate 'Lys-20' of histone H4. A collaboration between AbbVie and the SGC has resulted in the discovery of A-196 [5], the first potent and selective chemical probe for SUV420H1 and SUV420H2. The in vitro activity of A-196 includes inhibition of SUV420H1 with IC50 = 25 nM and SUV420H2 with IC50 = 144 nM for methylation of H4K20me and greater than 100-fold selectivity over other histone methyltransferases and non-epigenetic targets. In cell assays, A-196 inhibits the di- and tri-methylation of H4K20me in multiple cell lines with IC50 < 1 µM. in vitro / biochemical potency Mechanism of action Properties Physical and chemical properties for A-196 Molecular weight 358.1 Molecular formula C18H16Cl2N4 IUPAC name 8,9-dichloro-N-cyclopentyl-5-(pyridin-4-yl)-3,4-diaza-bicyclo[4.4.0]deca-1(10),2,4,6,8-pentaen-2-amine MollogP 5.04 PSA 42.6 No. of chiral centres 0 No. of rotatable bonds 3 No. of hydrogen bond acceptors 3 No. of hydrogen bond donors 1 Physical and chemical properties for A-197 Molecular weight 408.1 Molecular formula C19H22Cl2N4O2 IUPAC name (8,9-dichloro-5-cyclopentylamino-3,4-diaza-bicyclo[4.4.0]deca-1(10),2,4,6,8-pentaen-2-yl)-(4-hydroxy-piperidin-1-yl)-methanone MollogP 3.689 PSA 65.82 No. of chiral centres 0 No. of rotatable bonds 4 No. of hydrogen bond acceptors 5 No. of hydrogen bond donors 2 SMILES: A-196: [H]N(C1CCCC1)c1c2cc(c(cc2c(c2ccncc2)nn1)[Cl])[Cl] A-197: C1CCC(C1)Nc1c2cc(c(cc2c(C(N2CCC(CC2)O)=O)nn1)[Cl])[Cl] InChI: A-196:InChI=1S/C18H16Cl2N4/c19-15-9-13-14(10-16(15)20)18(22-12-3-1-2-4-12)24-23-17(13)11-5-7-21-8-6-11/h5-10,12H,1-4H2,(H,22,24) A-197: InChI=1S/C19H22Cl2N4O2/c20-15-9-13-14(10-16(15)21)18(22-11-3-1-2-4-11)24-23-17(13)19(27)25-7-5-12(26)6-8-25/h9-12,26H,1-8H2,(H,22,24) InChIKey: A-196: ABGOSOMRWSYAOB-UHFFFAOYSA-N A-197: NGGSLWXNDXYNJL-UHFFFAOYSA-N Selectivity ProfileSelectivity of A-196 is selective against 29 methyltransferases Selectivity of A-196 against epigenetic reader domains Cell-based Assay DataCell Assay Co-crystal structures Please wait whilst the interactive viewer is loaded! Main features 1. A-196 in complex with SUV420H1 and SAM 2. Close-up of A-196 in peptide binding pocket showing key H-bonds. 3. Overlay of A-196/SAM from SUV420H1 structure with H4K20me2 peptide from SUV420H2 structure. References[1] Jorgensen S, Schotta G, Sorenson CS. (2013) Histone H4 Lysine 20 methylation: key player in epigenetic regulation of genomic integrity. Nucleic Acids Research 41: 2797-806. [2] Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, et al. (2004) A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev. 18:1251–1262. [3] Sanders SL, Portoso M, Mata J, Bahler J, Allshire RC, et al. (2004) Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell; 119:603–614. [4] Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, et al. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391-400. [5] Bromberg KD, Mitchell TR, Upadhyay AK, Jakob CG, Jhala MA, et al. (2017 Jan 23) The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat Chem Biol.